Friday - March 20, 2026
Lynavoy Approved by the FDA for Cholestatic Pruritus in Patients With Primary Biliary Cholangitis
March 20, 2026
LONDON, England, March 20 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on March 19, 2026:

* * *

Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)

* Lynavoy, an ileal bile acid transporter (IBAT) inhibitor, is the first medicine approved in the US for the treatment of cholestatic pruritus in patients with PBC

* Up to 89% of . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products